OPRK1 and myeloid sarcoma: Activating the KOR by agonists, such as U50,488 or nalfurafine,alleviates disease symptoms in the EAE model, by promoting oligodendrocytedifferentiation and remyelination, as well as immune cell modulation.30−32 Thus, targeting the KOR represents an intriguing strategy to developnovel therapeutics for the treatment of pain and MS.30−32